Eagle Pharmaceuticals Inc. (EGRX) 59.30 $EGRX Health

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 11:00 AM

Eagle Pharmaceuticals Inc. (EGRX) 59.30 $EGRX

Health Care Stock Check: Complementary Research on Aduro BioTech, XBiotech, Eagle Pharma, Steadymed and Flex Pharma
PR Newswire - Thu Apr 23, 6:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
XBIT: 22.94 (-4.50), ADRO: 36.00 (-0.39), EGRX: 59.30 (-1.62), FLKS: 22.56 (-0.35), STDY: 9.95 (-0.19)

Eagle Pharmaceuticals to Present at Deutsche Bank 40th Annual Health Care Conference
Business Wire - Wed Apr 22, 3:30PM CDT
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced today that Scott Tarriff, President and Chief Executive Officer, and David Riggs, Chief Financial Officer, will present at the Deutsche Bank 40th Annual Health Care Conference as follows:
DB: 34.26 (+0.11), EGRX: 59.30 (-1.62)

Eagle Pharmaceuticals: Even After 350% Rally, Shares Have Upside
Bret Jensen - at Seeking Alpha - Wed Apr 22, 11:33AM CDT

EGRX: 59.30 (-1.62)

Will Eagle Pharmaceuticals (EGRX) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 6:31AM CDT
Will Eagle Pharmaceuticals (EGRX) Continue to Surge Higher?
EGRX: 59.30 (-1.62)

3 Top Healthcare Stocks Surging Higher This Year
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 18, 11:03AM CDT
Aging baby boomers and an increasingly insured population are driving healthcare utilization higher, and that has made stocks in this industry some of the market's best performers over the past three years. A number of healthcare stocks are soaring...
ESPR: 104.60 (-4.29), AZN: 71.79 (-1.34), HZNP: 31.75 (+0.97), TEVA: 64.41 (+1.16), EGRX: 59.30 (-1.62), HPTX: 45.97 (-0.11)

High Potency Recovery Supplements Combined with Increased Global Distribution Channels & New Branding Partnerships Fuels Growth Potential in the Pharmaceutical & Nutritional Supplement Industries
PR Newswire - Wed Apr 15, 7:35AM CDT
For consumers wanting to use supplements to improve their nutrition and sport performance through pharmaceutical and nutritional supplements usage plans, pharma grade products and supplements made with high-quality ingredients become top concern along with compliance and FDA regulations. Specialty pharmaceutical & Nutritional Supplement Companies in focus today are: Axxess Pharma Inc. (OTC: AXXE), GNC Holdings, Inc. (NYSE: GNC), Vitamin Shoppe (NYSE: VSI), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and BioLife Solutions (NASDAQ: BLFS)
VSI: 42.98 (-0.15), GNC: 47.17 (+0.30), TEVA: 64.41 (+1.16), EGRX: 59.30 (-1.62), BLFS: 2.02 (+0.08)

Teva and Eagle Pharmaceuticals reports US FDA accepts the rapid infusion bendamustine NDA for review for both CLL and indolent B-cell NHL
M2 - Wed Apr 15, 5:45AM CDT
Pharmaceutical company Teva Pharmaceutical Industries (NYSE:TEVA)(TASE:TEVA Eagle Pharmaceuticals (NasdaqGM:EGRX) on Tuesday jointly revealed that the New Drug Application (NDA) for a liquid bendamustine hydrochloride (HCl) rapid infusion product has been accepted for filing by the US Food and Drug Administration (FDA).
TEVA: 64.41 (+1.16), EGRX: 59.30 (-1.62)

Nasdaq stocks posting largest percentage increases
AP - Tue Apr 14, 4:58PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
HTBX: 6.89 (-0.71), DOVR: 8.43 (-0.05), STCK: 18.98 (+0.32), CLVS: 92.03 (+1.78), ORMP: 7.45 (+0.08), BIND: 6.84 (-0.33), EGRX: 59.30 (-1.62), VLTC: 11.54 (+0.50), BCLI: 4.14 (+0.02), REPH: 11.88 (+1.04)

FDA accepts Eagle Pharma's NDA for rapid infusion bendamustine
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 8:32AM CDT

TEVA: 64.41 (+1.16), EGRX: 59.30 (-1.62)

Teva and Eagle Pharmaceuticals Announce NDA for Bendamustine Rapid Infusion Product Accepted for Filing
Business Wire - Tue Apr 14, 7:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) today announce that the New Drug Application (NDA) for a liquid bendamustine hydrochloride (HCl) rapid infusion product has been accepted for filing by the U.S. Food and Drug Administration (FDA). The Prescription Drug User Fee Act (PDUFA) goal date for a decision on this NDA by the FDA is December 2015.
TEVA: 64.41 (+1.16), EGRX: 59.30 (-1.62)

Eagle Pharmaceuticals hires David M. Pernock to board
M2 - Tue Apr 14, 5:39AM CDT
Pharmaceutical company Eagle Pharmaceuticals (NasdaqGM:EGRX) revealed on Monday the appointment of David M. Pernock to its board of directors.
EGRX: 59.30 (-1.62)

Eagle Pharmaceuticals Appoints David M. Pernock to Its Board of Directors
Business Wire - Mon Apr 13, 7:00AM CDT
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or "the Company"

, today announced that David M. Pernock, an experienced biotechnology and pharmaceutical executive with over 25 years of industry experience, has been appointed to its Board of Directors effective immediately.
EGRX: 59.30 (-1.62)

Eagle Pharmaceuticals receives new low-sodium Bendamustine patent in the US
M2 - Wed Apr 08, 6:44AM CDT
Pharmaceutical company Eagle Pharmaceuticals (NasdaqGM: EGRX) reported on Tuesday the receipt of the United States Patent and Trademark Office's (USPTO) patent for the use of rapid infusion bendamustine for treating patients requiring restricted fluid and/or sodium intake.
EGRX: 59.30 (-1.62)

Teva Pharmaceutical: There Is A Lot To Like About This Stock
Musings of a Banker - at Seeking Alpha - Tue Apr 07, 11:45AM CDT

ACT: 295.41 (-2.95), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16), LLY: 71.58 (-0.82), ASPX: 100.88 (-0.01), ABBV: 66.07 (+1.82), EGRX: 59.30 (-1.62), BMY: 65.80 (-0.20)

Eagle Pharmaceuticals Announces New Patent for Low-Sodium Bendamustine
Business Wire - Tue Apr 07, 9:51AM CDT
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company"

today announced that the United States Patent and Trademark Office ("USPTO"

has granted Patent No. 9,000,021 for the use of bendamustine for treating patients requiring restricted fluid and/or sodium intake. The patent issued today expires in March 2033.
EGRX: 59.30 (-1.62)

Eagle Pharmaceuticals to Present at Needham & Company's 14th Annual Healthcare Conference
Business Wire - Thu Apr 02, 3:30PM CDT
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) announced today that Scott Tarriff, President and Chief Executive Officer, and David Riggs, Chief Financial Officer, will present at Needham & Company's 14th Annual Healthcare Conference as follows:
EGRX: 59.30 (-1.62)

Eagle Pharmaceuticals (EGRX) in Focus: Stock Surges 10.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 7:37AM CDT
Eagle Pharmaceuticals Inc. (EGRX) was a big mover last session, as the company saw its shares rise nearly 11% on the day.
SRDX: 26.53 (+0.03), EGRX: 59.30 (-1.62)

Eagle Pharmaceuticals prices public offering of common shares at USD42.00 per share
M2 - Wed Mar 18, 6:35AM CDT
Pharmaceutical company Eagle Pharmaceuticals (Nasdaq:EGRX) said on Tuesday that it has priced a public offering of 1,320,276 common stock at USD42.00 per share.
EGRX: 59.30 (-1.62)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BASIS Bellevue Expands with New K-4 Campus

A New Era for Young Learners in Bellevue When a community-driven school like BASIS Independent Bellevue makes a move to expand, it doesn't happen in a vacuum. They're not just building another campus—they're aiming to sculpt the future right here in Bellevue, and boy, do they have a plan. The new Lower School campus opening come Fall 2027 is dedicated to kiddos in...

Yellow River Basin Firms Focus on Global Expansion

Shandong's Bold Move on the Global Stage Imagine the bustling city of Jinan, Shandong's capital, humming with the energy of ambitious enterprises ready to leap into the global arena. That's exactly what unfolded at the conference aimed at forging international ties under the Belt and Road Initiative (BRI). For those out of the loop, this ain't just another business...

H.R. 10549: Hope Charities Pushes for Pharmacy Freedom

Hope Charities Takes a Stand for Patients In Prairieville, Hope Charities is throwing its weight behind a bill they believe is brewing up a patient revolution. The Patients Choice in Specialty Pharmacy Act, otherwise known as H.R. 10549, sparked by Representatives Neal Dunn and Joe Wilson, tackles the comfortable partnerships some insurers have been enjoying with their...

Smirnoff Launches Marvel Event with $12.99 Offer

Smirnoff's Bold Move to Ride Marvel's Coattails Here we are, watching a vodka brand hitch its wagon to a Hollywood juggernaut. Smirnoff has announced a fan experience to toast Marvel Studios' "Avengers: Doomsday." Of course, this isn't just about clinking glasses; it's a marketing stunt dressed in superhero tights. The impressive part? They’re selling the razzmatazz for...

Markel Stays the Course: Solid Q3 Results in 2026

Markel Group's Steady Climb Doesn't Falter Diving right into it, Markel Group's latest figures prove they're not just treading water. The insurance giant, trading under NYSE:MKL, reported solid third quarter results for 2026. And while some numbers might not be breaking records, they sure paint a picture of a company that's weathering the market with some grit. The...

JumpCloud Tackles Compliance in the AI Era

By Kelly Martin Updated Oct 28, 2026 Category News Views 110

Compliance in a Changing Tech Landscape JumpCloud's stepping up in this brave new world riddled with tech and AI agents. They've got fresh platform features in their arsenal that'll keep organizations audit-ready day in and day out. Now, if you think compliance is just for the accountants to fret over, think again. In the agentic era, these advanced marvels—AI agents...

Photocure's Q3 2026: Revenue Plateau and CFO Shakeup

The Bladder Cancer Scene: Steady as She Goes Sometimes, you look at numbers and find tranquility, like staring into still waters. That's the scene over at Photocure ASA with their latest Q3 results. Clocking in with revenues of NOK 134.2 million from their Hexvix®/Cysview® products, they're barely flinching from last year's NOK 134.1 million. Is it a victory or a...

Jamaica's Tourism Rebounds Post-Hurricane Challenges

Weathering the Storm: A New Chapter for Jamaica It's been nearly a year since Hurricane Melissa hit, and Jamaica is proving that it won't be pushed around by nature's whims. The island's tourism industry, once battered, is now showing remarkable resilience. With hotels and villas reopening and shaking off the dust, it's safe to say Jamaica is back on its feet, and it's...

Aker BP's Q3 2026: Strong Earnings Fuel Optimism

Third Quarter Overview: Riding the Wave Aker BP's third quarter report is a raucous symphony of successes that have the market nodding in admiration. Marking significant strides with their offshore projects, the company seems to be in a cavalier mood as it boasts higher sales volumes and promising financials. Net production came in at 374 mboepd, dampened slightly by...

Fidelis Care Opens $120K Workforce Grants for Aid

Fidelis Care Steps Up Workforce Engagement Fidelis Care's latest move introduces a fresh shot at tackling two birds with one stone—economic and health stability for Medicaid members. The Workforce Pathways to Health and Economic Mobility grants present up to $120,000 in support for New Yorkers, an attempt aimed squarely at reducing the vicious cycle that traps many in...